These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30487125)

  • 1. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
    Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
    Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
    Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
    Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia.
    Sanchez-Lopez E; Ghia EM; Antonucci L; Sharma N; Rassenti LZ; Xu J; Sun B; Kipps TJ; Karin M
    Cell Death Differ; 2020 Jul; 27(7):2206-2216. PubMed ID: 31992855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
    Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
    Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.
    Quijada-Álamo M; Hernández-Sánchez M; Rodríguez-Vicente AE; Pérez-Carretero C; Rodríguez-Sánchez A; Martín-Izquierdo M; Alonso-Pérez V; García-Tuñón I; Bastida JM; Vidal-Manceñido MJ; Galende J; Aguilar C; Queizán JA; González-Gascón Y Marín I; Hernández-Rivas JÁ; Benito R; Ordóñez JL; Hernández-Rivas JM
    Blood Cancer J; 2021 Jul; 11(7):127. PubMed ID: 34244476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
    Haselager M; Thijssen R; West C; Young L; Van Kampen R; Willmore E; Mackay S; Kater A; Eldering E
    Cell Death Differ; 2021 May; 28(5):1658-1668. PubMed ID: 33495554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
    Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
    Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription.
    Buggins AG; Pepper C; Patten PE; Hewamana S; Gohil S; Moorhead J; Folarin N; Yallop D; Thomas NS; Mufti GJ; Fegan C; Devereux S
    Cancer Res; 2010 Oct; 70(19):7523-33. PubMed ID: 20736369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.
    Haselager MV; Thijssen R; Bax D; Both D; De Boer F; Mackay S; Dubois J; Mellink C; Kater AP; Eldering E
    Mol Oncol; 2023 Jun; 17(6):1112-1128. PubMed ID: 36550750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
    Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
    Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
    Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
    Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
    Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex.
    Maas C; Tromp JM; van Laar J; Thijssen R; Elias JA; Malara A; Krippner-Heidenreich A; Silke J; van Oers MH; Eldering E
    Cell Death Dis; 2013 Aug; 4(8):e782. PubMed ID: 23990022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
    Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
    Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
    Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ
    Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
    Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
    Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
    Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
    Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.